Institutional & Insider Ownership
2.8% of GBS shares are held by institutional investors. Comparatively, 19.4% of NeuroMetrix shares are held by institutional investors. 0.3% of GBS shares are held by company insiders. Comparatively, 7.3% of NeuroMetrix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares GBS and NeuroMetrix”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GBS | $440,000.00 | 60.24 | -$8.31 million | ($0.56) | -3.18 |
| NeuroMetrix | $3.03 million | 3.09 | -$6.53 million | ($4.59) | -0.99 |
Volatility and Risk
GBS has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, NeuroMetrix has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500.
Profitability
This table compares GBS and NeuroMetrix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GBS | N/A | -85.64% | -54.42% |
| NeuroMetrix | -203.71% | -42.56% | -39.26% |
Summary
NeuroMetrix beats GBS on 8 of the 11 factors compared between the two stocks.
About GBS
GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
About NeuroMetrix
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Receive News & Ratings for GBS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GBS and related companies with MarketBeat.com's FREE daily email newsletter.
